These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Treatment of hepatitis C virus infection in patients with concurrent human immunodeficiency virus infection]. Peters L; Lindhardt BØ Ugeskr Laeger; 2006 Oct; 168(42):3604-8. PubMed ID: 17069721 [TBL] [Abstract][Full Text] [Related]
25. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129 [TBL] [Abstract][Full Text] [Related]
26. Improving anti-hepatitis C virus therapy. Pol S; Mallet VO Expert Opin Biol Ther; 2006 Sep; 6(9):923-33. PubMed ID: 16918259 [TBL] [Abstract][Full Text] [Related]
27. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study. Milazzo L; Caramma I; Mazzali C; Cesari M; Olivetti M; Galli M; Antinori S J Antimicrob Chemother; 2010 Apr; 65(4):735-40. PubMed ID: 20118492 [TBL] [Abstract][Full Text] [Related]
28. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041 [TBL] [Abstract][Full Text] [Related]
29. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. Morishima C; Polyak SJ; Ray R; Doherty MC; Di Bisceglie AM; Malet PF; Bonkovsky HL; Sullivan DG; Gretch DR; Rothman AL; Koziel MJ; Lindsay KL; J Infect Dis; 2006 Apr; 193(7):931-40. PubMed ID: 16518754 [TBL] [Abstract][Full Text] [Related]
30. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. Shire NJ; Welge JA; Sherman KE J Viral Hepat; 2007 Apr; 14(4):239-48. PubMed ID: 17381715 [TBL] [Abstract][Full Text] [Related]
31. Treatment duration for genotypes 2 and 3: still confusing after all these years. Jensen DM J Clin Gastroenterol; 2010 Sep; 44(8):527-8. PubMed ID: 20628314 [No Abstract] [Full Text] [Related]
32. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Maynard M; Pradat P; Gagnieu MC; Souvignet C; Trepo C Antivir Ther; 2008; 13(4):607-11. PubMed ID: 18672540 [TBL] [Abstract][Full Text] [Related]
33. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416 [TBL] [Abstract][Full Text] [Related]
35. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection. Trembling PM; Tanwar S; Dusheiko GM Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560 [TBL] [Abstract][Full Text] [Related]
36. Hepatitis C: epidemiology, diagnosis, natural history and therapy. Pol S; Vallet-Pichard A; Corouge M; Mallet VO Contrib Nephrol; 2012; 176():1-9. PubMed ID: 22310776 [TBL] [Abstract][Full Text] [Related]
37. New therapeutic strategies in HCV: second-generation protease inhibitors. Clark VC; Peter JA; Nelson DR Liver Int; 2013 Feb; 33 Suppl 1():80-4. PubMed ID: 23286850 [TBL] [Abstract][Full Text] [Related]
38. [Inhibitors of hepatitis C virus--current standards and status of investigations]. Godzik P; Komorowski M; Cielecka-Kuszyk J; Madaliński K Przegl Epidemiol; 2010; 64(4):473-8. PubMed ID: 21473060 [TBL] [Abstract][Full Text] [Related]
39. Specifically targeted antiviral therapy for hepatitis C virus. Parfieniuk A; Jaroszewicz J; Flisiak R World J Gastroenterol; 2007 Nov; 13(43):5673-81. PubMed ID: 17963291 [TBL] [Abstract][Full Text] [Related]
40. Recent advance in antiviral drugs for hepatitis C. Liu J; Shi S; Zhuang H; Luo G Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Nov; 36(11):1025-36. PubMed ID: 22169716 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]